Valuation
- Market cap
- 0
- Revenue TTM
- $2,220,000
- Net income TTM
- $-8,420,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -379.28%
- Debt to equity
- 0.00
Trading
- Volume
- 800
- Avg volume
- —
- Day's range
- $0.00 – $0.04
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate in...
Show more
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 415-512-7740
- Address
- 100 Pine Street, Suite 500, San Francisco, United States
Latest news
No headlines yet.
